Testing BMS-986525 alone or with pumitamig in small cell lung cancer
Tests BMS-986525, alone or with pumitamig, in adults with small cell lung cancer.
Plain-language title generated from the registry record
Registry title: A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Key facts
- Where
- Beijing and Shanghai, ChinaSee the 2 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose small cell lung cancer came back or stopped responding to treatment, after at least 1 platinum-based chemotherapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Small cell lung cancer that has come back or has not responded to treatment (relapsed/refractory), confirmed by tissue or cell tests.
- Earlier treatment
- Must have had at least 1 platinum-based chemotherapy. Where the usual first treatment includes an anti-PD-(L)1 therapy, the cancer must have progressed on it, or the person cannot have it or has no access to it.
Main reasons for not taking part
- Untreated cancer spread to the brain or spinal cord (CNS metastases)
- Active, known or suspected autoimmune disease
- Earlier organ or tissue allograft (donor transplant)
- Other exclusion criteria set by the study protocol may apply
Read by machine on 12 November 2026.
Where in China
- Beijing, Beijing MunicipalityHospital not named in the registryContact: Site 0029Not yet recruiting
- Shanghai East HospitalShanghai, ChinaContact: Caicun Zhou, Site 0028Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07325136EU 2025-524090-16-00
- Record updated
- 14 September 2026
- Original description
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung CancerRead full original descriptionShow less
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
Inclusion: Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC); Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines; In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.
Exclusion: Participants must not have had a prior organ or tissue allograft; Participants must not have an active, known or suspected autoimmune disease; Participants must not have any untreated CNS metastases; Other protocol-defined Inclusion/Exclusion criteria apply.